Exhibit 10.8
AMENDMENT NUMBER TWO TO CLINICAL
TRIAL AGREEMENT
THIS AMENDMENT NUMBER TWO TO THE
CLINICAL TRIAL AGREEMENT (the “Amendment”) is effective
December 1, 2009 (“Effective Date”) The General
Hospital Corporation d/b/a Massachusetts General Hospital, a
not-for-profit corporation organized under the laws of
Massachusetts with its principal place of business at 55 Fruit
Street, Boston, MA 02114 (“Institution”) and CytoDyn,
Inc., a publicly traded corporation organized under the laws of
Colorado with its principal place of business at 1511 Third Street,
Santa Fe, New Mexico 87505 (“Company”).
RECITALS
|
|
A.
|
INSTITUTION has
previously entered into a Clinical Trial Agreement to perform the
study protocol entitled “An observational study to
determine the in-vitro immunologic and virology activity of
Cytolin,” with Company on 28 September 2009 (the
“Agreement”) and amended it on October 14,
2009.
|
|
|
B.
|
The parties now
desire to further amend the Agreement
|